Just as a disciplined a soccer player might pass on a hopeful shot in favor of a better chance later on, the biopharma venture capital market reflected a preference for de-risked assts over platforms ...

The FDA has rejected a rare blood disease candidate from Disc Medicine, a compound that been granted expedited review through ...

In 2025, Moderna spent $3.1 billion on R&D, a 31% decrease from the $4.5 billion budget (PDF) in 2024 and a further drop from ...

"The FDA rejected Moderna's application for filing because the company refused to follow very clear FDA guidance from 2024 to ...

After a string of high-profile regulatory rebukes, Biohaven’s CEO believes red tape is getting in the way of patient well-being, particularly for those with rare diseases. | After a string of ...

BridgeBio is hoping infigratinib will get another shot at approval after the medicine hit the key goals of a phase 3 study in ...

Takeda’s real estate downsize will add to the region’s growing office sublease market. A January 2026 CBRE report on the ...

Ultragenyx Pharmaceutical's employees were already braced for changes as the biopharma considered how to rebound from a pair ...

After a preliminary look at the numbers, the company says revenues in its fiscal 2023 and 2024 years "may have been ...

Madrigal Pharmaceuticals is continuing to splash the cash this year on liver disease drugs it can combine with its own ...

One month after Integra LifeSciences recalled its wound and burn devices amid safety concerns, the medtech company is cutting ...

Just months after laying off a quarter of its workforce to fund a phase 2 study of its bloodstream infection preventive ...